Efficacy and Safety Comparisons of Four Approved Chimeric Antigen Receptor T‐Cell Therapies in Multiple Myeloma
Hematological Oncology · 2026-03 · 44 (2)
DOI: 10.1002/hon.70179 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Hematological Oncology, online erschienen am 21.02.2026. Verfasst von Zhiqiang Song und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality, 2024 Shanghai Talents Plan.
Abstract (Originalsprache)
Despite significant advances in novel therapies, multiple myeloma (MM) remains incurable due to inevitable relapse. Chimeric antigen receptor (CAR) T‐cell therapy is an innovative immunotherapy that has demonstrated remarkable efficacy in patients with relapsed/refractory (R/R) MM. To date, four B‐cell maturation antigen (BCMA)‐targeting CAR T‐cell therapies have been approved in the United States and China for the treatment of R/R MM: idecabtagene vicleucel, ciltacabtagene autoleucel, equecabtagene autoleucel, and zevorcabtagene autoleucel. Although these four CAR T‐cell therapies have achieved encouraging response rates in R/R MM, a comprehensive comparative analysis of their efficacy and toxicity profiles is still lacking. In this review, we compare the efficacy and safety of these four approved BCMA‐directed CAR T‐cell therapies. We also discuss potential factors underlying the observed differences and highlight strategies that may further improve the clinical outcomes of this revolutionary therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
- Department of Hematology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
ORCID-Profile: Zhiqiang Song, Qingcheng Fu, Juan Du
Förderung
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
- 2024 Shanghai Talents Plan
Zitieren
APA
Song, Z., Fu, Q., & Du, J. (2026). Efficacy and Safety Comparisons of Four Approved Chimeric Antigen Receptor T‐Cell Therapies in Multiple Myeloma. Hematological Oncology, 44(2). https://doi.org/10.1002/hon.70179
Vancouver
Song Z, Fu Q, Du J. Efficacy and Safety Comparisons of Four Approved Chimeric Antigen Receptor T‐Cell Therapies in Multiple Myeloma. Hematological Oncology. 2026;44(2). doi:10.1002/hon.70179
BibTeX
@article{Song2026,
author = {Song, Zhiqiang and Fu, Qingcheng and Du, Juan},
title = {Efficacy and Safety Comparisons of Four Approved Chimeric Antigen Receptor T‐Cell Therapies in Multiple Myeloma},
journal = {Hematological Oncology},
year = {2026},
volume = {44},
number = {2},
doi = {10.1002/hon.70179}
}
EUVIMED